[HTML][HTML] 湖南省首例Paxlovid 治疗新型冠状病毒奥密克戎BA. 5 变异株复阳病例报道
陈美平， 郭婷， 周志国， 陈东， 周海波 - Journal of Central South …, 2022 - ncbi.nlm.nih.gov
报告1 例口服奈玛特韦/利托那韦(nirmatrelvir/ritonavir， Paxlovid) 治愈出院的新型冠状病毒
肺炎(coronavirus disease 2019， COVID-19) 复阳的病例资料。 患者初次感染严重急性呼吸 …
肺炎(coronavirus disease 2019， COVID-19) 复阳的病例资料。 患者初次感染严重急性呼吸 …
SARS-CoV-2 Omicron BA. 5 infection recurrence after Paxlovid treatment: The first case report in Hunan Province.
M Chen, T Guo, Z Zhou, D Chen… - … nan da xue xue bao. Yi …, 2022 - europepmc.org
We report a case of coronavirus disease 2019 (COVID-19) patient who was cured by oral
administration of nirmatrelvir/ritonavir (Paxlovid). The patient was treated with Paxlovid after …
administration of nirmatrelvir/ritonavir (Paxlovid). The patient was treated with Paxlovid after …
Should Paxlovid be prescribed for patients with severe COVID‐19 in the late course of infection? A case report
Q Li, Y He, J Liu, X Lu, Z Zhou, Y Kang… - Medicine …, 2023 - Wiley Online Library
The infection of the coronavirus disease 2019 (COVID‐19) is often accompanied by
pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in …
pneumonia with both high incidence and mortality. Paxlovid is commonly prescribed in …
[PDF][PDF] COVID-19 rebound after Paxlovid treatment: a case series and review of literature
S Alshanqeeti, A Bhargava - Cureus, 2022 - cureus.com
Since the declaration of COVID-19 as a pandemic in 2020, several therapies have been
developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is …
developed to reduce symptoms of COVID-19 infection and prevent progression. Paxlovid is …
[HTML][HTML] REBOUND COVID-19 AFTER PAXLOVID IN 2 RELATED FAMILY MEMBERS
P Periyasamy, TL Fen, N Kori, UA Zainulabid - International Journal of …, 2023 - Elsevier
Intro On May 24, 2022, the CDC issued a healthcare advisory after reports of COVID-19
symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment …
symptoms returning (COVID-19 rebound) in certain patients two to eight days after treatment …
Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature
DW Yang, MJ Ju, H Wang, YC Jia… - Journal of Clinical …, 2023 - Wiley Online Library
Background The pandemic the coronavirus disease 2019 (COVID‐19) has created a global
health crisis. Although Paxlovid is recommended for the early‐stage treatment of mild‐to …
health crisis. Although Paxlovid is recommended for the early‐stage treatment of mild‐to …
326 例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析
陈华炎， 江东波， 郭春连， 杨家琪， 黎雨欣， 蔡伟明 - 中国药物警戒, 2024 - zgywjj.com
目的探讨奈玛特韦片/利托那韦片(Paxlovid) 治疗新型冠状病毒感染(COVID-19) 的安全性,
为临床用药提供参考. 方法通过电子病历系统收集2022 年12 月15 日至2023 年2 月15 …
为临床用药提供参考. 方法通过电子病历系统收集2022 年12 月15 日至2023 年2 月15 …
[HTML][HTML] 感染奥密克戎变异株的2019 冠状病毒病轻型和普通型患者核酸检测转阴时间影响因素分析
C Yijie, C Zhuomin, W Xiaohua, H XIONG… - Journal of Zhejiang …, 2022 - ncbi.nlm.nih.gov
感染奥密克戎变异株的2019冠状病毒病轻型和普通型患者核酸检测转阴时间影响因素分析- PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Comparison of therapeutic effects between monotherapy and combination therapy of Lopinavir/Ritonavir and Arbidol in COVID-19.
W Chen, C Chen, L Lyu, L Shi, C Pan, G Qiu, C Lu - 2020 - cabidigitallibrary.org
Objective To compare the therapeutic effects and adverse drug reaction between
monotherapy and combination therapy of Lopnavir/Ritonavir and Arbidol in coronavirus …
monotherapy and combination therapy of Lopnavir/Ritonavir and Arbidol in coronavirus …